Quantifying Methylergonovine Using LC–MS–MS
A team of researchers from China and the USA has developed a LC–MS–MS method for quantifying methylergonovine, a semi-synthetic ergot alkaloid used for the treatment and prevention of postpartum haemorrhage in human plasma.
Photo Credit: SCIEPRO/Getty Images
A team of researchers from China and the USA has developed a liquid chromatography coupled to tandem mass spectrometry (LC–MS–MS) method for quantifying methylergonovine (ME), a semi-synthetic ergot alkaloid used for the treatment and prevention of postpartum haemorrhage (PPH), in human plasma.1 PPH results in 44,000 to 86,000 deaths each year around the world, making it the leading cause of death during pregnancy.
ME has been used more recently in the control of refractory headaches and can be used as a chemosensitizer for cancer. However, this alkaloid sometimes causes elevated blood pressure, and so quantification in biological matrices is necessary.
The team extracted ME from 500-μL plasma samples using liquid–liquid extraction under alkaline conditions and detected using positive multi-reaction-monitoring mode (+MRM) mass spectrometry (MS). The method was validated according to US FDA guidelines and covered a working range from 0.025 to 10 ng/mL with a lower limit of quantification (LLOQ) of 0.025 ng/mL.
The team concluded that they have developed a rapid, sensitive, selective, and accurate LC–MS–MS method, which was successfully applied to a clinical pharmacokinetics study in female volunteers. They determined that it is suitable for both preclinical and clinical studies on ME. - K.M
Reference
- Hongxiang Lou et al., Journal of Chromatography B1011, 62–68 (2016).
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
